Endocrine Abstracts

Background: Alpelisib is an α-selective PI3K inhibitor indicated for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2–), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression or after endocrine therapy. Hyperglycemia is the most common adverse event (up to 60%) associated with its use. It occurs more frequently and lasts longer in patients with pred...

Introduction: Our objective is to determine the profile of patients with differentiated thyroid cancer (DTC) attended in our center and the therapeutic approach employed.Methods: Retrospective review of medical records from patients treated for DTC during the years 2013 and 2014.Results: Data from 387 patients, 84% female, 96% Caucasian, mean follow up of 10.82 years. The average age at diagnosis was 44.24 years, 77% had normal thy...